International Research Collaboration Aims to Personalise Prevention and Treatment of Cardiovascular Diseases
33 leading international partners, supported by the Innovative Health Initiative (IHI), have teamed up to launch the research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment. By creating one database consisting of data from more than 1 million patients and using artificial intelligence, partners will look for new strategies to shift from a one-size-fits-all approach to personalised care.
MAASTRICHT, Netherlands, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) has launched to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk.
Cardiovascular disease is very prevalent worldwide with enormous socio-economic impact. It is still the most common cause of death, despite significant advances in therapy. Due to population ageing and unhealthy lifestyle, the number of Europeans suffering from CVD currently exceeds 85 million and is still on the rise. This underscores the critical need for better care pathways to reduce the impact of CVD.
“As doctors, we are mostly bound to a one-size-fits-all approach while treating our patients with CVD. Our mission however, within iCARE4CVD, is to personalise diagnosis and management of CVD to improve both outcome and patient satisfaction. We will achieve this by collecting data of more than 1 million subjects in a federated database, analysing them using artificial intelligence (AI) and prospectively validating personalized treatments during the second half of iCARE4CVD,” said Prof Hans-Peter Brunner-La Rocca, coordinator of iCARE4CVD and cardiologist at Maastricht University and Maastricht University Medical Center+ (Maastricht UMC+).
To improve patient outcomes, iCARE4CVD aims to improve four aspects of current care:
1) Early diagnosis and classification into clinically meaningful subgroups
2) Risk stratification defining urgency for intervention
3) Prediction of individual treatment response
4) Inclusion of outcomes based on patient perspectives
“CVD encompasses a range of intricate, chronic conditions, with atherosclerosis being the most prevalent. Many questions remain about why some individuals with risk factors develop CVD while others do not, and how CVD progresses to more severe stages. iCARE4CVD represents a significant stride towards a deeper comprehension of CVD and the customization of interventions at each stage, catering to individual needs much more effectively,” said Prof Kees Hovingh, Senior Medical Officer and iCARE4CVD Scientific Leader at Novo Nordisk.
The voices of people at risk for and those currently living with CVD will be at the heart of iCARE4CVD during the entire project, by using patients’ insights, opinions and wishes. They will help to translate the findings into a more patient-centric and equitable narrative around CVD and its multiple impacts on individuals from both a social and medical perspective.
iCARE4CVD will also investigate health outcomes in people with type 1 diabetes at risk of developing CVD, explains Dr Jeanette Soderberg, Director at JDRF. “With the help of such a large European collaboration, we will investigate the impact of novel therapies typically used in type 2 diabetes on clinically important outcomes in the traditionally underappreciated but growing population of type 1 diabetes at risk. With the help of biomarkers, we will also be able to determine who’s in most need for such intervention.”
iCARE4CVD has been granted €22 million in funding from the Innovative Health Initiative (IHI) - a joint undertaking of the European Commission and the European life science industry. The project officially kicked off its activities across Europe in October 2023 and will run until 31 March 2028.
|Start date:||01 October 2023|
|Budget:||€ 22 Mio|
|Coordination:||University Maastricht, Prof Hans-Peter Brunner-La Rocca|
|Project Lead:||Novo Nordisk A/S, Dr Nicholas Ciccone|
|Austria||Medizinische Universität Wien|
|Belgium||Thomas More Kempen VZW|
|Denmark||Novo Nordisk A/S|
|France||Bayer Healthcare SAS France|
Fondation Francophone pour la Recherche sur le Diabete
Huawei Technologies France
INSERM/Mondor Biomedical Research
|Germany||Charite - Universitaetsmedizin Berlin|
Evotec International GmbH
Deutsche Stiftung für chonisch Kranke
|Ireland||University College Dublin|
|Italy||Fondazione Human Technopole |
Instituto di ricerche farmacologiche Mario Negri
Erasmus Universitair Medisch Centrum Rotterdam
Leids Universitair Medisch Centrum
Nederlandse Organisatie voor toegepast natuurwetenschappelijk onderzoek
Philips Medical Systems Nederland BV
Stichting IMEC Nederland
Universitair Medisch Centrum Groningen
|Switzerland||Amgen (Europe) GmbH|
Roche Diagnostics International AG
Swiss Institute of Bioinformatics
|United Kingdom||Orbital Global|
The Queen’s University of Belfast
University of Glasgow
|United States||Eli Lilly and Company and its Affiliates|
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio, MedTech Europe and JDRF International.
The Innovative Health Initiative (IHI) is a public-private partnership (PPP) between the European Union and the European life science industries. The partners of IHI are the European Union, represented by the European Commission, and the European life science industry, represented by the industry associations COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe. The core goals at IHI, are to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. IHI has a total budget of €2.4 billion and is funded jointly by the EU and by industry associations representing Europe’s life science industries. For further information: www.ihi.europe.eu
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
For questions about this press release or requests for interviews, please contact:
Rik van Laake, press officer, Maastricht UMC+
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
VALOE EXTENDS THE SUBSCRIPTION PERIOD OF THE CONVERTIBLE BOND 1/202330.11.2023 15:15:00 CET | Press release
Valoe Corporation Stock Exchange Release 30 November 2023 at 16.15 (Finnish time) The Board of Directors of Valoe Corporation has resolved to extend the subscription period of the Convertible Bond 1/2023 disclosed on 14 July 2023 until 29 December 2023 at 6.00 pm. In Mikkeli on 30 November 2023 Valoe Corporation BOARD OF DIRECTORS For more information: CEO Iikka Savisalo, Valoe Corporation tel. +358 40 521 6082 email: firstname.lastname@example.org Distribution: Nasdaq Helsinki Oy Main media www.valoe.com Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides PV technology based on its own back contact technology and related projects, project design and technology consulting. Valoe also provides manufacturing technology for PV modules, module manufacturing lines, modules and key components for modules, as well as IBC solar cells manufactured at the Company’s factory in Lithuania. Valoe is headquartered in Mikkeli, Finland, with production faci
Scatec awarded battery storage project for 103 MW in government tender in South Africa30.11.2023 14:53:04 CET | Press release
Oslo, 30 November 2023: Scatec ASA has been awarded preferred bidder status for the Mogobe (Ferrum) battery energy storage project totalling 103 MW/ 412 MWh under the first bid window of the Battery Energy Storage Independent Power Producer Procurement Programme (BESIPPPP) in South Africa, by the Department of Mineral Resources and Energy. Scatec will dispatch power under a 15-year power purchase agreement (PPA). “This marks another significant achievement for Scatec in South Africa and for the renewable energy transition in the country. Today’s award reaffirms our standing as a leading renewable energy player in South Africa. We applaud the South African government’s commitment and dedication to the battery storage procurement programme,” says Scatec CEO Terje Pilskog. Building on the experience garnered from our hybrid solar and battery storage projects at Kenhardt, we have established ourselves as a frontrunner in the dispatchable renewable energy landscape of South Africa and the A
Correction: New terms for DK0009414252 only english version30.11.2023 14:47:05 CET | Press release
To Nasdaq Copenhagen A/S 30th November 2023 Announcement no. 111/2023 Final terms for bonds to be listed 5thDecember 2023 On 5th December 2023, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 29th, 2023. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely, Jyske Realkredit A/S www.jyskerealkredit.com Please observe that the Danish version of this announcement prevails. Attachments DK0009414096 - Final terms series 1 321.E.ok.25 IT1DK0009414179 - Final terms series 1 321.E.26 IT1DK0009414252 - Final terms series 1
Correction: Kun korrektion i den engelske version30.11.2023 14:47:05 CET | pressemeddelelse
, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Til Nasdaq Copenhagen A/S 30. november 2023 Meddelelse nr. 111/2023 Endelige vilkår for nye obligationer der noteres den 5. december 2023 Jyske Realkredit noterer den 5. december 2023 nye Særligt Dækkede Obligationer (SDO). Med denne meddelelse følger de endelige vilkår for obligationerne. Det samlede prospekt for obligationerne består af vedlagte endelige vilkår og det tidligere offentliggjorte ”Basisprospekt for udstedelse af Særligt Dækkede Obligationer (SDO), Realkreditobligationer (RO) og obligationer i medfør af § 15 i lov om realkreditlån og realkreditobligationer m.v. (§ 15 Obligationer)”, dateret 29. juni 2023. Jyske Realkredits basisprospekt er tilgængeligt på Jyske Realkredits hjemmeside jyskerealkredit.dk. Venlig hilsen Jyske Realkredit www.jyskerealkredit.dk Vedhæftede filer DK0009414252 - Endelige vilkår serie 1 321.E.EUR.26 IT1DK0009414096 - Endelige vilkår serie 1 321.E.ok.25 IT1DK0009414179 - Endelige vilkår serie 1 321.E.26 IT1
FRO – Q3 2023 Presentation30.11.2023 14:40:31 CET | Press release
Please find enclosed the presentation of Frontline plc´s third quarter 2023 results to be held on the webcast / conference call 30 November, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachment Presentation Q3 2023